Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”
Circulation · 04.08.2026 · 154 (5)
DOI: 10.1161/circulationaha.126.080757 ↗Kurz gefasst
Leserbrief in der Zeitschrift Circulation, erschienen am 04.08.2026. Verfasst von William F Fearon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA, (W.F.F., K.T., K.K.K.). Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA, (W.F.F., K.T., K.K.K.).
- VA Palo Alto Health Care System, CA (W.F.F.).
ORCID-Profile: William F Fearon, Kiran K Khush
Zitieren
APA
Fearon, W. F., Takahashi, K., & Khush, K. K. (2026). Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”. Circulation, 154(5). https://doi.org/10.1161/circulationaha.126.080757
Vancouver
Fearon WF, Takahashi K, Khush KK. Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”. Circulation. 2026;154(5). doi:10.1161/circulationaha.126.080757
BibTeX
@article{Fearon2026,
author = {Fearon, William F and Takahashi, Kuniaki and Khush, Kiran K},
title = {Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”},
journal = {Circulation},
year = {2026},
volume = {154},
number = {5},
doi = {10.1161/circulationaha.126.080757}
}
EUVIMED